Lubrizol and Polyhose launched a Chennai medical tubing facility, boosting India’s MedTech manufacturing, reducing imports, and enhancing healthcare innovation.
Lubrizol, a global leader in specialty chemical solutions, in partnership with Polyhose, a renowned manufacturer of fluid conveyance systems, has officially inaugurated a state-of-the-art medical manufacturing facility in Chennai, Tamil Nadu. The newly established plant is dedicated to producing precision-extruded medical tubing for minimally invasive medical devices, marking a significant step toward strengthening India’s rapidly expanding medical technology and healthcare sectors.
The facility has been developed to meet the growing demand for high-quality medical components required in advanced healthcare applications. As India continues to emerge as a major hub for medical device manufacturing, the collaboration between Lubrizol and Polyhose is expected to play a crucial role in enhancing local production capabilities while supporting the country’s ambition to become more self-reliant in healthcare manufacturing.
Designed as a world-class operation, the Chennai facility has been certified under ISO 13485, the internationally recognized quality management standard for medical device manufacturing. This certification reflects the site’s commitment to maintaining the highest levels of product quality, regulatory compliance, and operational excellence. Customers will benefit from a dependable domestic source of premium medical tubing produced under stringent quality control systems that align with the rigorous standards followed throughout Lubrizol’s global manufacturing network.
The investment represents an important milestone for both companies. By establishing local production capabilities in India, Lubrizol can better serve its customers not only within the country but also across international markets. The facility enhances supply chain efficiency, shortens lead times, and provides greater flexibility in meeting the evolving needs of medical device manufacturers worldwide.
Manufacturing operations at the site will focus on producing precision-extruded tubing using a broad portfolio of advanced, high-performance materials. These include polyamides, nylon, Pebax®, polypropylene, polyethylene, and Lubrizol’s proprietary medical-grade thermoplastic polyurethane (TPU). Such materials are widely used in the development of minimally invasive medical devices, including catheters, delivery systems, and other critical healthcare applications where precision, durability, flexibility, and biocompatibility are essential.
The new manufacturing site is expected to significantly increase India’s production capacity for precision medical tubing, a key component in modern medical devices. By expanding domestic manufacturing capabilities, the facility supports national efforts to reduce dependence on imported medical components and strengthen local supply chains. This development aligns with broader government and industry initiatives aimed at fostering innovation, encouraging investment in healthcare manufacturing, and improving the country’s competitiveness in the global MedTech market.
Beyond industrial benefits, the facility is also expected to contribute positively to patient care. Increased local availability of high-quality medical tubing can help medical device manufacturers access critical components more efficiently, ultimately supporting the production of advanced healthcare products. This may improve accessibility to safe, reliable, and technologically advanced medical devices for patients both in India and abroad.
The inauguration of the Chennai facility demonstrates the shared commitment of Lubrizol and Polyhose to advancing healthcare innovation, strengthening manufacturing excellence, and supporting the continued growth of India’s medical technology ecosystem. Through this strategic investment, the two companies are helping build a stronger foundation for the future of medical device manufacturing while reinforcing India’s position as a key player in the global healthcare supply chain.
Market Impact: The inauguration of Lubrizol and Polyhose’s advanced medical tubing facility in Chennai is expected to have a positive impact on the medical-grade polymers and specialty materials market. The new plant will increase domestic production of precision-extruded medical tubing used in minimally invasive medical devices, thereby strengthening India’s medical device manufacturing ecosystem. The facility’s ability to process high-performance materials such as polyamides, nylon, Pebax®, polypropylene (PP), polyethylene (PE), and medical-grade thermoplastic polyurethane (TPU) is likely to boost demand for these specialty polymers in the long term.
From a pricing perspective, the immediate impact on chemical commodities tracked by ChemAnalyst is expected to be limited, as the facility primarily serves a niche, high-value medical applications segment rather than bulk commodity markets. However, sustained production growth and expansion of India's MedTech sector could gradually increase consumption of engineering plastics and specialty elastomers. This may provide moderate demand support for TPU, nylon, and Pebax-related value chains, particularly within the domestic market.
Polypropylene and polyethylene prices are unlikely to witness any significant change solely due to this development, given their large global production capacities and diverse end-use sectors. Similarly, broader petrochemical markets will remain driven by feedstock costs, supply-demand balances, and macroeconomic conditions. Overall, the project is expected to support long-term demand growth for medical-grade polymers while having a neutral to slightly bullish impact on specialty polymer prices in India.
